دورية أكاديمية
أعرض في EDS

Seroprevalence and risk factors of HBV, HCV and HIV among hemodialysis patients: a multicenter cross-sectional study from Damascus Syria.

التفاصيل البيبلوغرافية
العنوان: Seroprevalence and risk factors of HBV, HCV and HIV among hemodialysis patients: a multicenter cross-sectional study from Damascus Syria.
المؤلفون: Altinawe J; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syria., Akkawi ME; Department of Pharmacy Practice, Faculty of Pharmacy, International Islamic University Malaysiam, Jalan Sultan Ahmad Shah, Bandar Indera Mahkota, Kuantan, Pahang, 25200, Malaysia. mhdeidak@gmail.com., Kharrat Helu N; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syria., Hassan Q; Department of Internal Medicine, Faculty of Medicine, Damascus University, Damascus, Syria., Nattouf AH; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syria.
المصدر: BMC infectious diseases [BMC Infect Dis] 2024 Mar 06; Vol. 24 (1), pp. 289. Date of Electronic Publication: 2024 Mar 06.
نوع المنشور: Multicenter Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Hepatitis C*/epidemiology , HIV-1*, Male ; Humans ; Infant ; Child, Preschool ; Child ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Female ; Hepacivirus ; Hepatitis B virus ; Cross-Sectional Studies ; Seroepidemiologic Studies ; Syria/epidemiology ; Risk Factors ; Antigens, Viral ; HIV Antibodies
مستخلص: Objective: The aim of this study is to determine the prevalence rates of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infections among hemodialysis (HD) patients as well as to identify associated risk factors.
Methodology: A multicenter cross-sectional study involved patients who had been on HD for at least three months. The study was conducted at five HD centers in Damascus, Syria from August 2019 to September 2021. HBsAg, HCV-Ab and HIV (antibody/antigen) seropositivity were identified using the third generation ELISA technique. Patients' information was extracted from their records and by face-to-face interview. Multiple logistic regression models were applied to identify risk factors associated with HBV or HCV seropositivity. The significance level was set at 5%.
Results: A total of 637 patients were included in the study with a mean age (SD) of 50.5 (15.6) years and 56.7% of them were men. The dialytic age ranged from one to thirty years with a mean (SD) of 6.10 (5.6) years. The prevalence of positive hepatitis B surface antigen, anti-HCV, co-infection of HBV and HCV, and anti-HIV (antibody/antigen) were 3.2%, 22.1%, 0.7%, and 0%, respectively. After controlling for co-variables, hepatitis B vaccine was the only predictor of seropositivity of HBV (OR: 0.15, 95% CI: 0.057-0.393, P < 0.001), as it significantly protected against contracting HBV. On the other hand, the dialytic age (OR: 1.42, 95% CI: 1.12-1.94, P = 0.032) and the dialysis center were significant factors affecting the prevalence of HCV.
Conclusions: The prevalence of HCV and HBV infections among HD patients in Damascus, Syria has decreased remarkably compared with the results from 2001. Nevertheless, it is still considered relatively high. Thus, there is an urgent need to strengthen the prevention and control measures for viral infection transmission in HD centers in Damascus.
(© 2024. The Author(s).)
References: Exp Ther Med. 2020 Jul;20(1):109-116. (PMID: 32509002)
Euro Surveill. 2020 Jul;25(29):. (PMID: 32720634)
Infection. 2001 Oct;29(5):262-5. (PMID: 11688903)
Iran J Kidney Dis. 2016 Sep;10(5):304-309. (PMID: 27721229)
Nephrol Dial Transplant. 2009 May;24(5):1598-603. (PMID: 19096083)
Saudi J Kidney Dis Transpl. 2014 May;25(3):672-9. (PMID: 24821177)
Ann Med Surg (Lond). 2018 Mar 16;29:1-4. (PMID: 29692888)
BMC Nephrol. 2018 Nov 3;19(1):304. (PMID: 30390638)
Am J Nephrol. 2000 Mar-Apr;20(2):103-6. (PMID: 10773609)
Hepat Mon. 2014 Jun 01;14(6):e17417. (PMID: 24976839)
BMC Infect Dis. 2016 Feb 01;16:41. (PMID: 26830673)
Semin Dial. 2019 Mar;32(2):93-98. (PMID: 30536715)
World J Nephrol. 2016 Jan 6;5(1):101-7. (PMID: 26788469)
Kidney Int. 2015 Feb;87(2):262-5. (PMID: 25635715)
Saudi J Kidney Dis Transpl. 2009 May;20(3):488-92. (PMID: 19414962)
Virol J. 2010 Sep 01;7:210. (PMID: 20809985)
Int J STD AIDS. 2021 Mar;32(3):257-265. (PMID: 33525959)
J Med Virol. 2012 Jan;84(1):52-5. (PMID: 22052648)
Int J Infect Dis. 2013 Oct;17(10):e832-7. (PMID: 23317526)
Saudi J Kidney Dis Transpl. 2009 Jan;20(1):140-6. (PMID: 19112237)
Arab J Nephrol Transplant. 2011 Jan;4(1):35-47. (PMID: 21469594)
East Mediterr Health J. 2016 Jul 10;22(4):267-73. (PMID: 27432409)
Kidney Int. 2003 Jun;63(6):2222-9. (PMID: 12753311)
World J Gastroenterol. 2017 Jan 7;23(1):151-166. (PMID: 28104991)
PLoS One. 2021 Jun 22;16(6):e0251570. (PMID: 34157037)
J Clin Exp Hepatol. 2013 Mar;3(1):24-8. (PMID: 25755468)
Kidney Int. 2022 Dec;102(6S):S129-S205. (PMID: 36410841)
Int J Nephrol. 2021 Nov 13;2021:1555775. (PMID: 34812291)
Int J Infect Dis. 1999 Summer;3(4):207-10. (PMID: 10575150)
Aliment Pharmacol Ther. 2022 Aug;56(4):558-569. (PMID: 35758763)
Hepat Res Treat. 2013;2013:860514. (PMID: 23533739)
فهرسة مساهمة: Keywords: Chronic kidney disease; Damascus; HBV; HCV; HIV; Hemodialysis; Hepatitis; Infection; Syria
المشرفين على المادة: 0 (Antigens, Viral)
0 (HIV Antibodies)
تواريخ الأحداث: Date Created: 20240306 Date Completed: 20240308 Latest Revision: 20240309
رمز التحديث: 20240309
مُعرف محوري في PubMed: PMC10916258
DOI: 10.1186/s12879-024-09177-4
PMID: 38448805
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2334
DOI:10.1186/s12879-024-09177-4